Drug Database
ZO

zolpidem tartrate (Intermezzo / zolpidem, TransOral)

✓ Approved

Transcept Pharmaceuticals · GABRA1 · 小分子

什么是 zolpidem tartrate?

zolpidem tartrate 是一种小分子,由Transcept Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名Intermezzo, zolpidem, TransOral
公司Transcept Pharmaceuticals
药物类别小分子
分子靶点GABRA1
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

作用机制

分子靶点

zolpidem tartrate 作用于 1 个分子靶点:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

zolpidem tartrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersInsomnia✓ Approved

相关研究文献

PubMedFrontiers in pharmacology2026-11-18

Hyperbolic heterogeneous graph learning for adverse drug reaction prediction, candidate prioritization, and pathway-based interpretation in pharmacovigilance.

Lv Ru R, Xu Xiaoyu X, Ji Yulin Y, Wei Jianxiang J et al.

Adverse drug reaction (ADR) prediction remains challenging because spontaneous reporting data leave many exposure unit-ADR associations unobserved and provide limited support for candidate prioritization and mechanistic interpretation. We developed MEG-HHGN, a mechanistic evidence-guided hyperbolic heterogeneous graph neural network. It represents exposure units as combinations of standardized drug names and routes of administration and integrates spontaneous reports with compounds, drug targets, ADR-related targets, and protein-protein interactions. Using 73,530 spontaneous reports collected in Jiangsu Province from 2010 to 2023, we evaluated MEG-HHGN against eight baseline methods through five-fold cross-validation. MEG-HHGN achieved AUC/AP/MCC values of 0.9550/0.9537/0.7917 in known-exposure-unit completion and 0.9090/0.9064/0.6587 in side-information-supported exposure-unit cold-start evaluation. Global scoring of unobserved exposure unit-ADR pairs produced a ranked candidate pool for pharmacovigilance review. Representative cases involving intravenous vinorelbine tartrate-myelosuppression and oral aspirin-proteinuria illustrated PPI-bridged and shared-target pathways, respectively. MEG-HHGN integrates route-aware prediction, candidate prioritization, and pathway-based interpretation in a unified framework to support signal triage, mechanistic hypothesis generation, and evidence review in post-marketing pharmacovigilance.

PMID 43047891
阅读全文 →
PubMedFood chemistry2026-11-17

The dual effect of potassium polyaspartate on wine tartaric stability: Potassium hydrogen tartrate stabilisation versus calcium tartrate supersaturation and co-precipitation.

Fioschi Gabriele G, Prezioso Ilaria I, Carrozzino Marco M, Allegretta Ignazio I et al.

Climate change has raised wine pH and calcium levels, making calcium tartrate (CaT) instability a significant concern in winemaking. Potassium polyaspartate (KPA) is used to prevent potassium bitartrate (KHT) precipitation, but its effect on CaT stability remains unclear. This research examined how KPA influences CaT stability in seven wines. KPA prevented KHT precipitation in all wines, lowering its saturation temperature from unstable range of 18.40-27.25 °C in untreated wines to stable range as low as 0.00-10.65 °C. The same treatment raised the mean saturation temperature of CaT from 18.08 °C to 21.28 °C, promoting CaT precipitation. Cold tests and electron microscopy confirmed KPA doesn't stop CaT crystals formation; these crystals can act as nucleation sites for KHT formation. The results suggest that KPA can alter ionic equilibria to favor CaT nucleation. Since CaT crystals can bypass KPA's inhibitory action on KHT, using this additive may not guarantee long-term tartaric stability in the bottle.

PMID 43044409
阅读全文 →
PubMedPsychotherapy and psychosomatics2026-11-16

Concomitant Psychotropic Medication Is Associated with Reduced Outcomes of Trauma-Focused Psychotherapy for Post-Traumatic Stress Disorder.

Steenen Serge A SA, van Westrhenen Roos R, Steenen Camilo C CC, Klausch L Thomas LT et al.

Psychotropic medications are frequently prescribed alongside trauma-focused psychotherapy for post-traumatic stress disorder (PTSD), yet their impact on treatment response remains uncertain. This study emulated target trials to examine the association between psychotropic co-medication at treatment onset and psychotherapy outcomes in a real-world PTSD cohort. A prospective cohort of 6,125 adults with chronic or delayed-onset PTSD received a standardized 2-8 day trauma-focused psychotherapy program, including daily prolonged exposure and eye movement desensitization and reprocessing (EMDR) therapy, at a Dutch psychotrauma center (2021-2024). Target trial emulation with double machine learning with inverse probability of treatment weighting estimated the effects of specific psychotropic co-medications versus non-use on changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores (range, 0-80) from pre-to post-treatment. Mean CAPS-5 scores improved by 25.7 points (Cohen's d = -2.30). Psychotropic co-medication (n = 1,382) was associated with reduced symptom improvement compared with non-use (model-estimated difference = -2.52 points; relative reduction = -9.4%, 95% CI = -10.0 to -8.9; d = -1.11, E = 10.0). This effect persisted at 6-month follow-up (d = -0.42). Antidepressants overall (d = -0.28; follow-up d = -0.56), amitriptyline (d = -0.51), and mirtazapine (d = -0.29) were consistently associated with poorer outcomes across sensitivity analyses. Similar patterns were observed for anticonvulsants, mood-stabilizing anticonvulsants, antipsychotics, fluoxetine, zolpidem, and zopiclone. Sensitivity analyses and E-values indicated robustness to unmeasured confounding. Several psychotropic co-medications were associated with reduced outcomes of evidence-based trauma-focused psychotherapy for PTSD. By identifying this as a potentially modifiable factor, psychotherapy outcomes may be optimized. Trials are warranted to evaluate whether tapering or substituting these agents improves outcomes.

PMID 43038311
阅读全文 →
PubMedNature and science of sleep2026-11-15

Acupuncture-Assisted Zolpidem Tartrate Tapering and Discontinuation in Patients with Chronic Insomnia Disorder Stabilized on Zolpidem: A Study Protocol for a Randomized Controlled Trial.

Liu Lumin L, Guo Zhicheng Z, Jiang Shihan S, Yang Ming M et al.

The prevalence of chronic insomnia disorder (CID) is relatively high and increases with age. The use of sedatives, along with the incidence of their adverse effects, is also rising, which can easily lead to health risks and negative outcomes. This study aims to evaluate the clinical efficacy and safety of acupuncture-assisted zolpidem tartrate tapering and discontinuation in patients with CID whose insomnia symptoms are clinically stable while taking zolpidem. This study is designed as a single-center, single-blind, randomized controlled trial.Ninety participants will be randomly assigned in a 1:1 ratio to either the acupuncture group or the sham acupuncture group. Each participant will undergo 24 sessions of either acupuncture or sham acupuncture, in conjunction with zolpidem tartrate tapering therapy, over a duration of 8 weeks, followed by a 4-week follow-up observation period. The primary outcome is the discontinuation rate of zolpidem tartrate at week 8. Secondary outcomes include the reduction rate of zolpidem tartrate, the discontinuation rates at weeks 10 and 12, frequency of zolpidem tartrate use (nights/week), average daily dose (mg/day), total weekly dose (mg/week), Insomnia Severity Index (ISI), Generalized Anxiety Disorder -7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Short Form Health Survey-12 (SF-12), sleep diary-related indicators, Dysfunctional Beliefs and Attitudes about Sleep Scale -16 (DBAS-16), Epworth Sleepiness Scale (ESS) and emergency medication usage. Adverse events will also be monitored throughout the study. Efficacy analyses will be conducted on the intention-to-treat population. The findings of the study may provide preliminary evidence for standardized protocols for reducing and ceasing zolpidem tartrate use through acupuncture assistance. Additionally, this research may offer useful references for patients with CID seeking to safely and effectively reduce or discontinue zolpidem tartrate. These findings may inform future clinical research and larger multicenter confirmatory studies. ITMCTR2026000497 (Registered on 10 Mar 2026) https://itmctr.ccebtcm.org.cn/mgt/project/view/2031287058080858112.

PMID 43034795
阅读全文 →
PubMedTherapeutic advances in psychopharmacology2026-11-15

A systematic review of case reports and case series of zolpidem in the diagnosis and treatment of catatonia.

Ahuja Niraj N, Hackett Harry H, Thorne Joseph J, Watson Stuart S et al.

Catatonia, commonly seen in psychiatric and medical practice, is often associated with increased morbidity and mortality. The neurotransmitter systems involved in catatonia include GABA, dopamine and glutamate. Benzodiazepines such as lorazepam, which act on GABA-A receptors, are used to confirm the diagnosis of catatonia, and are the mainstay of treatment. However, several patients with catatonia either don't respond to lorazepam or its use is not suitable or possible (e.g. due to supply issues). Zolpidem is a positive allosteric modulator of GABA-A receptors. There are an increasing number of case reports and one systematic review of its use in the diagnosis and treatment of catatonia. The objective of this systematic review is to explore the published evidence of zolpidem's efficacy as a diagnostic test and for treatment for catatonia. We systematically reviewed evidence for zolpidem use in diagnosis and/or treatment of catatonia, using the PRISMA guidelines. We identified 44 case reports and case series, with 79 patients who met the inclusion criteria through searches of PubMed, Medline, EMBASE, CINAHL, ProQuest and PsycInfo. 67 out of 79 patients (84.8%) with catatonia showed a positive response to zolpidem, with remission of catatonic symptoms in 24.1% of patients. The high response rate was evident regardless of its use as a challenge test (85.7%) or treatment (86.1%), either used alone (85.7%), or with a benzodiazepine (81.3%). The mean dose of zolpidem was 14.7mg, with a median of 10mg, and a range of 5 to 45mg, with a rapid mean time to response of 30.2 minutes. A few patients responded better to zolpidem at a higher dose and/or when used over a longer duration though this was not always the case. The response rate was higher in women (88.6%) as compared to men (64.7%). Although the results from this systematic review generate optimism for the use of zolpidem in diagnosis and treatment of catatonia, these results should be used with caution as there are no randomised controlled trials of zolpidem compared to placebo and/or lorazepam.

PMID 43034532
阅读全文 →
PubMedBrain communications2026-11-15

Pharmacological treatments in disorders of consciousness.

Saleh Christian C, Seyfzadeh Fatemeh F, Szymkowicz Emilie E, Alnagger Naji N et al.

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

PMID 43032840
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多zolpidem tartrate